AC Immune SAのBeta
AC Immune SAのBetaは何ですか。
AC Immune SAのBetaは0.82です。
Betaの定義は何ですか。
BETAは、株式が市場全体よりも多かれ少なかれ揮発性であるかどうかを示します。 1未満のベータは株式が市場よりも揮発性が低いことを示し、1より大きいベータは株式がより揮発性であることを示します。ボラティリティは、平均値周辺の価格の変動として測定されます。
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
NASDAQのセクタHealth CareにおけるBetaの企業と比べるAC Immune SA
AC Immune SAは何をしますか。
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
AC Immune SAと類似のbeta
- Punjab National BankのBetaは0.82です。
- ALSO AGのBetaは0.82です。
- PantronicsのBetaは0.82です。
- RIWIのBetaは0.82です。
- SFL LtdのBetaは0.82です。
- Tantech LtdのBetaは0.82です。
- AC Immune SAのBetaは0.82です。
- Greenlam IndustriesのBetaは0.82です。
- POCL EnterprisesのBetaは0.82です。
- Tech MahindraのBetaは0.82です。
- Southern Arc MineralsのBetaは0.82です。
- TSSのBetaは0.82です。
- LifeTech ScientificのBetaは0.82です。